United Therapeutics CorporationSilver Spring, MD United States
Company Description
United Therapeutics hopes its products will be in vein. Its injectable drug Remodulin treats pulmonary hypertension, which affects the blood vessels between the heart and lungs. The product is marketed directly and through distributors in North America, Europe, and other regions. Other hypertension treatments include Adcirca and Tyvaso. The company's development pipeline includes additional treatments for cardiovascular disease, as well as various cancers, respiratory conditions, and infectious diseases. United Therapeutics has divested its cardiac monitoring division.
| 1040 Spring St. | Phone: 301-608-9292 | http://www.unither.com |
| Silver Spring, MD 20910 | Fax: 301-608-9291 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
United Therapeutics Corporation Rankings
| #43 in FORTUNE's Fastest-Growing Companies (September 2011) | S&P 400 |
Executives
| 29 executives listed for United Therapeutics Corporation's Silver Spring, MD location. | ||
| Chairman and CEO | Martine Rothblatt | |
|---|---|---|
| Vice Chairman | Christopher Patusky | |
| President, COO, and Director | RogerJeffs | |
Financials
| Company Type | Public - NASDAQ: UTHR Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 543 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on United Therapeutics Corporation now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
